ETC
SMMT icon

Exchange Traded Concepts’s Summit Therapeutics SMMT Stock Holding History

Exchange Traded Concepts’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,328
Closed -$122K – 1497
2025
Q1 		$122K Buy
6,328
+647
+11% +$13K ﹤0.01% 1083
2024
Q4 		$101K Sell
5,681
-818
-13% -$15.9K ﹤0.01% 1139
2024
Q3 		$142K Sell
6,499
-39,252
-86% -$549K ﹤0.01% 1082
2024
Q2 		$357K Sell
45,751
-14,235
-24% -$76.9K 0.01% 748
2024
Q1 		$248K Sell
59,986
-14,985
-20% -$59.6K 0.01% 863
2023
Q4 		$196K Buy
74,971
+19,011
+34% +$39.1K 0.01% 790
2023
Q3 		$105K Sell
55,960
-18,073
-24% -$34.5K ﹤0.01% 878
2023
Q2 		$186K Buy
+74,033
New +$135K ﹤0.01% 810

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Exchange Traded Concepts's SMMT Position: Q2 2025 in Review

Exchange Traded Concepts sold out of Summit Therapeutics (SMMT) in Q2 2025, closing a stake of 6,328 shares — an estimated $122K sold.

Exchange Traded Concepts first reported a position in SMMT in Q2 2023 and held it in 8 quarters. The position peaked at $357K in Q2 2024. 238 funds tracked by Wall St. Rank hold SMMT as of Q2 2025.

  • Exchange Traded Concepts reported no remaining Summit Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Exchange Traded Concepts sold 6,328 Summit Therapeutics shares in Q2 2025, an estimated $122K.
  • Exchange Traded Concepts first reported a position in Summit Therapeutics in Q2 2023 and held it in 8 quarters.
  • Exchange Traded Concepts's Summit Therapeutics position peaked at $357K in Q2 2024.
  • 238 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2025.

Based on Exchange Traded Concepts's 13F filing for Q2 2025, filed 10 Jul 2025.